Why Wait? Investors Can Expect a More Proactive, Aggressive FDA
This article was originally published in RPM Report
Executive Summary
Comments made by former FDA offi cials and incoming leadership describe a scenario of nearcrisis and rock-bottom morale. Agency management is taking aggressive action to address those concerns. Investors have zeroed in on the new Commissioner(s).